{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:16:15Z","timestamp":1772151375416,"version":"3.50.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,8]]},"DOI":"10.7759\/cureus.98681","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T09:43:18Z","timestamp":1765186998000},"source":"Crossref","is-referenced-by-count":1,"title":["Severe Adverse Effects of Tirzepatide Overdose Requiring Intensive Care Unit Admission and Complex Rehabilitation"],"prefix":"10.7759","author":[{"given":"Mahmoud","family":"Sharafeldin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noor","family":"Alhamdan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayesha","family":"Khaliq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Mounjaro gains momentum in the UK\u2019s private obesity treatment market, outpacing Wegovy. (2024). Accessed. November 22, 2025: https:\/\/www.contemporaryhealth.co.uk\/medication\/mounjaro-gains-momentum-in-the-uks-private-obesity-treatment-market-o...."},{"key":"ref2","unstructured":"Nutrition support for adults. oral nutrition support, enteral tube feeding and parenteral nutrition. (2006). Accessed: November 22, 2025: https:\/\/www.nice.org.uk\/guidance\/cg32."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2015.1090295","article-title":"User's guide to mechanism of action and clinical use of GLP-1 receptor agonists","volume":"127","author":"Shaefer CF Jr","year":"2015","unstructured":"Shaefer CF Jr, Kushner P, Aguilar R. User's guide to mechanism of action and clinical use of GLP-1 receptor agonists. Postgrad Med. 2015, 127:818-26. 10.1080\/00325481.2015.1090295","journal-title":"Postgrad Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13230","article-title":"A review of GLP-1 receptor agonists in type 2 diabetes: a focus on the mechanism of action of once-weekly agents","volume":"45 Suppl 1","author":"Cornell S","year":"2020","unstructured":"Cornell S. A review of GLP-1 receptor agonists in type 2 diabetes: a focus on the mechanism of action of once-weekly agents. J Clin Pharm Ther. 2020, 45 Suppl 1:17-27. 10.1111\/jcpt.13230","journal-title":"J Clin Pharm Ther"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-020-00981-0","article-title":"The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type\u00a02 diabetes: the SURPASS clinical trials","volume":"12","author":"Min T","year":"2021","unstructured":"Min T, Bain SC. The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type\u00a02 diabetes: the SURPASS clinical trials. Diabetes Ther. 2021, 12:143-57. 10.1007\/s13300-020-00981-0","journal-title":"Diabetes Ther"},{"key":"ref6","unstructured":"Tirzepatide (Mounjaro) factsheet. (2023). Accessed. November 22, 2025: https:\/\/www.kentandmedwayformulary.nhs.uk\/media\/ieeh0ar4\/tirzepatide-mounjaro-factsheet.pdf."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2022.102427","article-title":"Adverse drug reactions of GLP-1 agonists: a systematic review of case reports","volume":"16","author":"Shetty R","year":"2022","unstructured":"Shetty R, Basheer FT, Poojari PG, Thunga G, Chandran VP, Acharya LD. Adverse drug reactions of GLP-1 agonists: a systematic review of case reports. Diabetes Metab Syndr. 2022, 16:102427. 10.1016\/j.dsx.2022.102427","journal-title":"Diabetes Metab Syndr"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1121387","article-title":"A systematic review of the safety of tirzepatide-a new dual GLP1 and GIP agonist - is its safety profile acceptable?","volume":"14","author":"Meng Z","year":"2023","unstructured":"Meng Z, Yang M, Wen H, Zhou S, Xiong C, Wang Y. A systematic review of the safety of tirzepatide-a new dual GLP1 and GIP agonist - is its safety profile acceptable?. Front Endocrinol (Lausanne). 2023, 14:1121387. 10.3389\/fendo.2023.1121387","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.12890\/2024_004357","article-title":"Tirzepatide-induced ketoacidosis in non-diabetic patients","volume":"11","author":"Iqbal PM","year":"2024","unstructured":"Iqbal PM, Maadarani OS, Bitar ZI. Tirzepatide-induced ketoacidosis in non-diabetic patients. Eur J Case Rep Intern Med. 2024, 11:004357. 10.12890\/2024_004357","journal-title":"Eur J Case Rep Intern Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.946133","article-title":"Exploring hypoglycemic ketoacidosis in nondiabetic patients on tirzepatide: is starvation the culprit?","volume":"25","author":"Bitar Z","year":"2024","unstructured":"Bitar Z, Abdelraouf HM, Maig RA, Maadarani O, Bitar ZZ, Dashti H. Exploring hypoglycemic ketoacidosis in nondiabetic patients on tirzepatide: is starvation the culprit?. Am J Case Rep. 2024, 25:e946133. 10.12659\/AJCR.946133","journal-title":"Am J Case Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1608657","article-title":"A retrospective observational study on case reports of adverse drug reactions (ADRs) to tirzepatide","volume":"16","author":"Huang M","year":"2025","unstructured":"Huang M, Liu G, Zhang C, Wang Y, Liu S, Zhao J. A retrospective observational study on case reports of adverse drug reactions (ADRs) to tirzepatide. Front Pharmacol. 2025, 16:1608657. 10.3389\/fphar.2025.1608657","journal-title":"Front Pharmacol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1210\/jcemcr\/luae156","article-title":"Euglycemic ketoacidosis from semaglutide in a patient without diabetes","volume":"2","author":"Sood N","year":"2024","unstructured":"Sood N, Bansal O, Garg R, Hoskote A. Euglycemic ketoacidosis from semaglutide in a patient without diabetes. JCEM Case Rep. 2024, 2:luae156. 10.1210\/jcemcr\/luae156","journal-title":"JCEM Case Rep"},{"key":"ref13","unstructured":"GLP-1 receptor agonists. reports of diabetic ketoacidosis when concomitant insulin was rapidly reduced or discontinued. (2019). Accessed: November 22, 2025: https:\/\/www.gov.uk\/drug-safety-update\/glp-1-receptor-agonists-reports-of-diabetic-ketoacidosis-when-concomitant-insul...."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.65858","article-title":"A rare case of severe folate deficiency-induced pancytopenia","volume":"16","author":"Abdullah A","year":"2024","unstructured":"Abdullah A, Shakoor EU, Sarwar S, Jamil TR, Hina A. A rare case of severe folate deficiency-induced pancytopenia. Cureus. 2024, 16:e65858. 10.7759\/cureus.65858","journal-title":"Cureus"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/443537-severe-adverse-effects-of-tirzepatide-overdose-requiring-intensive-care-unit-admission-and-complex-rehabilitation","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T09:43:19Z","timestamp":1765186999000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/443537-severe-adverse-effects-of-tirzepatide-overdose-requiring-intensive-care-unit-admission-and-complex-rehabilitation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.98681","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,8]]}}}